ACOR logo

Acorda Therapeutics, Inc.

ACOR

ACOR: Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

more

Show ACOR Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of ACOR by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by ACOR's directors and management

Government lobbying spending instances

  • $7,500 May 01, 2017 Issue: None
  • $22,500 Apr 18, 2017 Issue: Budget/Appropriations
  • $22,500 Jan 10, 2017 Issue: Budget/Appropriations
  • $22,500 Oct 07, 2016 Issue: Budget/Appropriations
  • $22,500 Jun 29, 2016 Issue: Budget/Appropriations
  • $22,500 Apr 19, 2016 Issue: Budget/Appropriations
  • $22,500 Jan 15, 2016 Issue: Budget/Appropriations
  • $22,500 Oct 14, 2015 Issue: Budget/Appropriations
  • $22,500 Jul 01, 2015 Issue: Budget/Appropriations
  • $30,000 Jan 23, 2014 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $30,000 Oct 21, 2013 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $50,000 Oct 21, 2013 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $30,000 Oct 21, 2013 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $50,000 Jan 22, 2013 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $50,000 Oct 19, 2012 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $50,000 Jul 17, 2012 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $60,000 Apr 20, 2012 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $60,000 Jan 18, 2012 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $50,000 Oct 20, 2011 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $50,000 Jul 20, 2011 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $50,000 Apr 20, 2011 Issue: Budget/Appropriations Health Issues Science/Technology
  • $30,000 Jan 20, 2011 Issue: Health Issues Budget/Appropriations Pharmacy
  • $60,000 Oct 20, 2010 Issue: Health Issues Budget/Appropriations Pharmacy
  • $60,000 Jul 20, 2010 Issue: Budget/Appropriations Health Issues Pharmacy
  • $60,000 Apr 20, 2010 Issue: Health Issues Pharmacy Budget/Appropriations
  • $60,000 Jan 20, 2010 Issue: Pharmacy Budget/Appropriations Health Issues
  • $60,000 Oct 15, 2009 Issue: Health Issues Budget/Appropriations Pharmacy
  • $60,000 Jul 17, 2009 Issue: Pharmacy Health Issues Budget/Appropriations
  • $60,000 Apr 17, 2009 Issue: Health Issues Budget/Appropriations Pharmacy
  • $60,000 Jan 16, 2009 Issue: Pharmacy Health Issues Budget/Appropriations
  • $60,000 Oct 16, 2008 Issue: Budget/Appropriations Health Issues Pharmacy
  • $60,000 Jul 21, 2008 Issue: Health Issues Budget/Appropriations Pharmacy
U.S. Patents

New patents grants

  • Patent Title: Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure Feb. 01, 2022
  • Patent Title: Methods of reducing extravasation of inflammatory cells Oct. 12, 2021
  • Patent Title: Carbonate prodrugs and methods of using the same Oct. 05, 2021
  • Patent Title: Methods for detecting cardiac damage Jul. 27, 2021
  • Patent Title: Water-soluble acetaminophen analogs Jun. 01, 2021
  • Patent Title: Methods for cardiomyocyte survival, proliferation or differentiation by nrg-2 Jul. 21, 2020
  • Patent Title: Method for achieving desired glial growth factor 2 plasma levels Jun. 09, 2020
  • Patent Title: Compositions and methods for treatment during non-acute periods following cns neurological injury Jun. 02, 2020
  • Patent Title: Water-soluble acetaminophen analogs Oct. 15, 2019
  • Patent Title: Carbonate prodrugs and methods of using the same Aug. 13, 2019
  • Patent Title: Compositions and methods of using chondroitinase abci mutants Jun. 18, 2019
  • Patent Title: Methods for detecting cardiac damage Apr. 16, 2019
  • Patent Title: Methods for treating congestive heart failure Mar. 19, 2019
  • Patent Title: Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2 Sep. 04, 2018
  • Patent Title: Compositions and methods of using chondroitinase abci mutants Jun. 05, 2018
  • Patent Title: Water-soluble acetaminophen analogs May. 29, 2018
  • Patent Title: Compositions and methods for promoting neuronal outgrowth May. 01, 2018
  • Patent Title: Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure May. 01, 2018
  • Patent Title: Hepatoprotectant acetaminophen mutual prodrugs Apr. 24, 2018
  • Patent Title: Methods of using sustained release aminopyridine compositions Mar. 27, 2018
  • Patent Title: Sustained release aminopyridine composition Mar. 20, 2018
  • Patent Title: Methods of reducing extravasation of inflammatory cells Dec. 12, 2017
  • Patent Title: Compositions and methods of using chondroitinase abci mutants Dec. 05, 2017
  • Patent Title: Methods for detecting cardiac damage Sep. 12, 2017
  • Patent Title: Compositions and methods including a recombinant human mab that promotes cns remyelination Sep. 05, 2017
  • Patent Title: Methods and compositions for administration of trpv1 agonists Sep. 05, 2017
  • Patent Title: Method for achieving desired glial growth factor 2 plasma levels Aug. 29, 2017
  • Patent Title: Carbonate prodrugs and methods of using the same Jun. 20, 2017
  • Patent Title: Compositions and kits for the removal of irritating compounds from bodily surfaces Jan. 24, 2017
  • Patent Title: Proteoglycan degrading mutants for treatment of cns Dec. 27, 2016
  • Patent Title: Compositions and methods for treatment during non-acute periods following cns neurological injury Nov. 22, 2016
  • Patent Title: Compositions and methods for promoting neuronal outgrowth Oct. 18, 2016
  • Patent Title: Compositions and methods of using chondroitinase abci mutants Aug. 09, 2016
  • Patent Title: Compositions and methods of using chondroitinase abci mutants Aug. 02, 2016
  • Patent Title: Methods for detecting cardiac damage May. 03, 2016
  • Patent Title: Carbonate prodrugs and methods of using the same Mar. 22, 2016
  • Patent Title: Method for achieving desired glial growth factor 2 plasma levels Mar. 01, 2016
  • Patent Title: Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure Dec. 01, 2015
  • Patent Title: Compositions and methods of using chondroitinase abci mutants Aug. 11, 2015
  • Patent Title: Use of a neuregulin to treat peripheral nerve injury Jul. 14, 2015
  • Patent Title: Acetaminophen conjugates, compositions and methods of use thereof May. 05, 2015
  • Patent Title: Carbonate prodrugs and methods of using the same Mar. 31, 2015
  • Patent Title: Fusion proteins for the treatment of cns Dec. 09, 2014
  • Patent Title: Formulations for the treatment of pain Nov. 18, 2014
  • Patent Title: Compositions and kits for the removal of irritating compounds from bodily surfaces Nov. 18, 2014
  • Patent Title: Compositions and methods of using chondroitinase abci mutants Oct. 07, 2014
  • Patent Title: Compositions and methods for promoting neuronal outgrowth Jul. 22, 2014
  • Patent Title: Carbonate prodrugs and methods of using the same May. 27, 2014
  • Patent Title: Methods and compositions for administration of trpv1 agonists May. 27, 2014
  • Patent Title: Methods of reducing extravasation of inflammatory cells Mar. 25, 2014
WallStreetBets

Number of mentions of ACOR in WallStreetBets Daily Discussion

ACOR News

Recent insights relating to ACOR

CNBC Recommendations

Recent picks made for ACOR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ACOR

Corporate Flights

Flights by private jets registered to ACOR